OpGen, Inc. (OPGN) :0.64
52 Week Range 0.5400 - 13.6000
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Mon, June 26, 2023 at 1:30 PM GMT+2
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.
The opposition division of European Patent Office ruled to maintain the patent as granted with minor modifications.
ROCKVILLE, Md., June 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.
The patent with the title GENETIC RESISTANCE PREDICTION AGAINST ANTIMICROBIAL DRUGS IN MICROORGANISM USING STRUCTURAL CHANGES IN THE GENOME was granted in Europe on January 6, 2021 and in China on January 10, 2023.
In September 2021, an opposition was filed by a Swedish opponent against the patent grant by the European Patent Office. In a hearing on Thursday, June 22, 2023, the opposition division of the European Patent Office ruled in favor of maintaining the patent as granted with a minor amendment to one of the claims.
The patent as maintained broadly covers the prediction of AMR in pathogens based on any genetic determinants involving two or more nucleotides.
The patent is an important component of the comprehensive intellectual property portfolio protecting Ares Genetics' unique database ARESdb and machine learning based approaches for predicting phenotypic antibiotic susceptibility and resistance directly from genomic data, an approach also referred to as “genomic AST.” Under the patent, both the computational identification of genetic determinants of AMR and genomic AST can be carried out, in order to diagnose AMR infections in patient samples.
“The patent covers the use of alignment-free methods, which are not only more computing resource efficient, but are also generally required to discover and resolve more complex structural variants, which is particularly important in this context,” says Dr. Arne Materna, CEO and Managing Director of Ares Genetics. “We therefore welcome the favorable ruling by the European Patent Office, an outcome that we believe underscores the validity, novelty and potential value of similar pending patent applications in our portfolio.”
OpGen believes that bacterial whole genome sequencing (WGS) is becoming the method of choice for detecting and controlling healthcare associated outbreaks. Genomic AST as covered in the patent has the potential to expand the utility of WGS beyond outbreak-surveillance into the realm of diagnostic applications to inform therapy.
About OpGen, Inc.
OpGen, Inc. (Rockville, Md, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
time for a strong recovery:
Jun 21, 2023 0.5900 0.6300 0.5400 0.6300 0.6300 364,754
Jun 19, 2023 0.6000 0.6300 0.5400 0.6300 0.6300 527,300
Jun 12, 2023 0.6400 0.7200 0.5800 0.6000 0.6000 1,968,700
Jun 05, 2023 0.7000 0.7200 0.5600 0.6000 0.6000 413,900
May 29, 2023 0.7100 0.7700 0.6900 0.7000 0.7000 357,600
May 22, 2023 0.7500 0.8000 0.6890 0.7050 0.7050 413,300
May 15, 2023 0.7700 0.7760 0.6440 0.7460 0.7460 420,900
May 08, 2023 0.7900 0.8680 0.7100 0.7520 0.7520 535,100
May 01, 2023 0.7600 0.8080 0.5500 0.7640 0.7640 1,197,700
Apr 24, 2023 0.9600 0.9930 0.7390 0.7940 0.7940 5,012,100
Apr 17, 2023 1.1400 1.2700 0.9340 0.9800 0.9800 2,665,500
Apr 10, 2023 1.2800 1.3000 1.0900 1.1400 1.1400 632,200
Apr 03, 2023 1.3400 1.3800 1.2900 1.3100 1.3100 512,800
Mar 27, 2023 1.5300 1.5600 1.1500 1.3300 1.3300 2,066,500
Mar 20, 2023 1.4800 1.6000 1.3100 1.4900 1.4900 2,480,700
Mar 13, 2023 1.0600 1.4700 0.9860 1.4700 1.4700 5,374,700
Mar 06, 2023 1.1100 1.2470 0.9300 1.1000 1.1000 3,861,800
Feb 27, 2023 1.0200 1.1300 1.0000 1.1000 1.1000 795,600
Feb 20, 2023 1.1800 1.2900 0.9900 1.0300 1.0300 1,145,700
Feb 13, 2023 1.4400 1.4400 0.9800 1.1800 1.1800 2,933,200
Feb 06, 2023 1.7600 2.0500 1.4000 1.4100 1.4100 4,334,900
Jan 30, 2023 1.9200 2.0800 1.6600 1.7400 1.7400 1,635,600
Jan 23, 2023 2.2700 2.3100 1.8200 1.9200 1.9200 2,118,100
Jan 16, 2023 2.6100 2.7210 2.2300 2.3000 2.3000 647,800
Jan 09, 2023 2.3900 2.7300 2.2200 2.6000 2.6000 1,294,300
Jan 02, 2023 2.8000 3.8000 2.5000 2.6500 2.6500 1,347,185
Dec 26, 2022 2.5800 3.2000 2.2200 2.8200 2.8200 505,600
Dec 19, 2022 2.8200 3.0000 2.4000 2.6000 2.6000 592,145
Dec 12, 2022 2.4200 9.0600 2.3400 2.6200 2.6200 13,543,83
